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Abstract: One of the most important threats to global human health is the increasing incidences
of metabolic pathologies (including obesity, type 2 diabetes and non-alcoholic fatty liver disease),
which is paralleled by increasing consumptions of hypercaloric diets enriched in simple sugars.
The challenge is to identify the metabolic pathways affected by the excessive consumption of these
dietary components when they are consumed in excess, to unravel the molecular mechanisms
leading to metabolic pathologies and identify novel therapeutic targets to manage them. Mechanistic
(mammalian) target of rapamycin (mTOR) has emerged as one of the key molecular nodes that
integrate extracellular signals, such as energy status and nutrient availability, to trigger cell responses
that could lead to the above-mentioned diseases through the regulation of lipid and glucose
metabolism. By activating mTOR signalling, excessive consumption of simple sugars (such as
fructose and glucose), could modulate hepatic gluconeogenesis, lipogenesis and fatty acid uptake
and catabolism and thus lipid deposition in the liver. In the present review we will discuss some of
the most recent studies showing the central role of mTOR in the metabolic effects of excessive simple
sugar consumption.
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1. Introduction
Mechanistic (formerly mammalian) target of rapamycin (mTOR) is a serine/threonine protein
kinase that forms the catalytic centre of two multi-protein complexes termed mTORC1 and mTORC2,
which have different compositions and responses to upstream signals [1,2]. As it is shown in Figure 1,
both complexes share the core proteins mTOR and mammalian lethal with SEC13 protein 8 (mLST8),
the Tti1/Tel2 complex and the inhibitory protein DEP domain-containing mTOR-interacting protein
(DEPTOR). The mTORC1 complex contains regulatory-associated protein of mTOR (Raptor) and
the inhibitory subunit proline-rich Akt substrate of 40 kDa (PRAS40), whereas mTORC2 contains
rapamycin-insensitive companion of mTOR (Rictor) and the regulatory proteins Protor1/2 and mSin1.
Both complexes are activated by insulin and related growth factors, such as insulin-like growth factors,
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while mTORC1 can also be activated by nutrients (amino acids, cholesterol and simple sugars), oxygen
and the cellular energy status (sensed via ATP levels) [1,3].
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inhibitory  protein  DEP  domain‐containing  mTOR‐interacting  protein  (DEPTOR).  In  addition, 
mTORC1  contains  regulatory‐associated  protein  of  mTOR  (Raptor)  and  the  inhibitory  subunit 
proline‐rich Akt  substrate of 40 kDa  (PRAS40), whereas mTORC2  contains  rapamycin‐insensitive 
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The downstream effects of mTORC1 and mTORC2 activity (reviewed in Reference [4]) are also 
different.  Briefly, mTORC1  activation  induces  cellular  growth  through:  (i)  activation  of mRNA 
translation,  driven  by  the  phosphorylation  of  the  ribosomal  protein  S6  kinases  (S6K1/2), which 























phosphorylates  several substrates,  including  its autophosphorylation at Ser‐2481, which  indicates 
mTOR‐specific catalytic activity [7].   
Figure 1. Components of mTORC1 and mTORC2 complexes. mTORC1 and mTORC2 share the core
proteins mTOR and mammalian lethal with SEC13 protein 8 (mLST8), the Tti1/Tel2 complex and the
inhibitory protein DEP do ain-containing mTOR-interacting protein (DEPTOR). In addition, mTORC1
contains regulatory-associated protein of mTOR (Raptor) and the inhibitory subunit proline-rich Akt
substrate of 40 kDa (PRAS40), whereas mTORC2 contains rapamycin-insensitive companion of mTOR
(Rictor) and the regulatory proteins Protor1/2 and mSin1.
The downstream effects of mTORC1 and mTORC2 activity (reviewed in Reference [4]) are also
different. Briefly, TORC1 activation induces cellular growth through: (i) activation of mRNA
translation, driven by the phosphorylatio of the ribosomal protein S6 kinases (S6K1/2), which activate
sever l subst at s associated wit the initiation of mRNA translation and the phosphorylation of
eIF4E binding protein (4EBP), which release fac or eIF4E to enable the forma io of the tr slation
initiation complex; (ii) promot on of m tabolic effects ncluding increas d de n vo lipid synthesis via
the ac ivation f sterol response element-binding pr tein (SREBP) and a shift to glycolysi inst ad of
ox ative phosphorylation; and (iii) inhibition of catabolic pathways such as autophagy, mainly by
the phosphoryl tion of UNC-51-like kinase 1 (ULK-1). By contrast, mTORC2 activation promotes cell
s rvival and proliferation thr ug the ph sphorylation of sever l kinases including Akt, which is one
of the main transducers of insulin signalling.
In summary, the role of mTOR complexes is to c ordinate cell responses to energy availability by
promoting or repressing anabolic and catabolic molecular p hways in response to different stimuli,
including nutrients and growth factors. This review focus s on mTOR regulation by a pecific typ of
nutrients (simple sugars) and its c nsequence on lipid and carbohydrate metabolism, aiming to ga n
insight into the mechanisms by which an excessive intake of simple sugars causes metabolic diseases
such as dyslipidaemia, diabetes and non-al oholic fatty liver dis ase (NAFLD).
2. Regulation of mTORC1 Activity by Simple Sugars
Of the two mTOR complexes, only mTORC1 seems to be regulated by simple sugars (Figure 2).
Direct regulation of mTORC1 activity by carbohydrate is less well known than that by amino acids.
Activation of mTORC1 by amino acids is initiate by the stimulatio of the Rag family of GTPases,
which recruits mTORC1 to the outer lysosomal m m rane [2]. Using mice that constitutively expres an
active form of RagA, Efeyan et al. showed that mTORC1 activation by carbo ydrates also involves the
Rag-GTPases [5,6]. This shared mechanism between amino cids and carbohydrates does not directly
activate m ORC1 but cause its lysosomal localization, where the R s-homolog enriche in brain (Rheb)
GTPase resides and activates mTORC1 b pr oting mTOR kinas activity. mTOR phosphorylates
several su strates, including its autophosphorylation at Ser-2481, which indic t s mTOR-specific
catalytic activity [7].












fructose  induced  mTOR  phosphorylation  by  increasing  Rheb  expression. We  did  not  detect  a 
significant  increase  in  the hepatic  levels of Rheb protein  in  female rats supplemented with  liquid 
fructose  for  two months  [8]. A cell‐based model of mTORC1 regulation by glucose proposed  that 
high glucose levels increased glycolytic flux and reduced the interaction of Rheb with GAPDH, thus 
increasing  the  availability  of  Rheb  to  interact  with  and  activate  mTORC1  [12].  Our  co‐
immunoprecipitation  experiments  showed  that  this was not  the mechanism  for  fructose‐induced 
mTORC1 activation, since Rheb‐GAPDH and Rheb‐mTOR interactions were not affected in the livers 
of fructose‐supplemented rats [8].   
Carbohydrates  also  regulate  mTORC1  indirectly  via  adenosine  monophosphate‐activated 
protein kinase (AMPK), which senses the fluctuations  in energy levels due to glucose availability. 
AMPK  is another cellular energy sensor  that  is activated by  increased AMP/ATP  ratio caused by 
either reduced ATP production or excessive ATP consumption [13]. AMPK has the opposite role to 
that of the mTOR system. While mTOR is activated by high energy availability and promotes anabolic 
routes  to use  this energy  in cell growth and proliferation, AMPK  senses  low energy statuses,  for 
example glucose deprivation and promotes catabolic processes to obtain energy. Glucose deprivation 





activates  the  upstream  mTOR  inhibitor  TSC1/TSC2  complex  [15,16]  or  direct  inhibition  by 
phosphorylating Raptor [17]. It is not yet known which of these mechanisms predominate but it has 
Figure 2. Proposed mechanisms of mTORC1 activity regulation by simple sugars. mTORC1 activation
by simple sugars might be mediated by several mechanisms, including (i) Rag-GTPases activation,
which cause mTORC1 lysosomal localization, (ii) increased glycolytic flux, which might increase Rheb
availability and inhibit AMPK activity, (iii) increased plasma insulin levels and (iv) increased ER stress.
In studies conducted by our group in female rats supplemented with 10% (w/v) liquid
fructose for different periods of time (two weeks, two months and seven months), we consistently
showed a marked increase in hepatic mTOR phosphorylation at Ser-2481 [8–10]. As Rheb
overexpression has been reported to promote the phosphorylation of mTOR at this position [11],
we explored whether fructose induced mTOR phosphorylation by increasing Rheb expression.
We did not etect a significant increase in the hepatic levels of Rheb protein in female rats
suppleme ted with liquid fructose for two months [8]. A cell-based model of mTORC1 regulation
by glucose proposed that high glucose levels increased glycolytic flux and reduced the interaction
of Rheb with GAPDH, thus increasing the availability of Rheb to interact with and activate
mTORC1 [12]. Our co-immunoprecipitation experiments showed that this was not the mechanism
for fructose-induced mTORC1 activation, since Rheb-GAPDH and Rheb-mTOR interactions were not
affected in the livers of fructose-supplemented rats [8].
Carbohydrates also regulate mTORC1 indirectly via adenosine monophosphate-activated protein
kinase (AMPK), which senses the fluctuations in energy levels due to glucose availability. AMPK is
another cellular energy sensor that is activated by increased AMP/ATP ratio caused by either reduced
ATP production or excessive ATP consumption [13]. AMPK has the opposite role to that of the
mTOR system. While mTOR is activated by high energy availability and promotes anabolic routes to
use this energy in cell growth and proliferation, AMPK senses low energy statuses, for example
glucose deprivation and promotes catabolic processes to obtain energy. Glucose deprivation
activates AMPK not only by increasing the AMP/ATP ratio but also by depletion of the glucose
metabolite fructose-1,6-biphosphate. Reduced levels of this metabolite facilitate the formation of
an AMPK-containing protein complex in the lysosomal membrane, which stimulates the kinase
LKB1 to phosphorylate and activate AMPK [14]. AMPK activation can inhibit the mTORC1 pathway
through two main mechanis s: phosphorylation of tuberous sclerosis co plex (TSC) 2 at Ser-1387,
which activates the upstream mTOR inhibitor TSC1/TSC2 complex [15,16] or direct inhibition by
phosphorylating Raptor [17]. It is not yet known which of these mechanisms predominate but it
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has been proposed that TSC2 phosphorylation may counteract growth factor-activated mTORC1,
whereas Raptor phosphorylation has been reported to inhibit basal mTORC1 activity [18].
When glucose enters the glycolytic pathway to form pyruvate for the tricarboxylic acid
(TCA) cycle, ATP is generated and AMPK is inhibited, which leads to mTORC1 activation.
However, before entering the glycolytic pathway, carbohydrates are phosphorylated by hexokinases
in an irreversible reaction that consumes ATP. Although this process is similar for all carbohydrates,
there are some differences. For example, glucose is phosphorylated first by glucokinase and after
isomerization the resulting molecule is phosphorylated by phosphofructokinase, whose activity
is tightly controlled by end-product inhibition (ATP and citrate) [19]. By contrast, fructose is
phosphorylated by fructokinase and enters the glycolytic pathway by skipping the negative
feedback control system. Moreover, fructose up-regulates fructokinase expression, thus inducing
its own metabolism. Therefore, despite both fructose and glucose phosphorylation consuming ATP,
this consumption is more rapid and intense for fructose, which may deplete ATP [20]. Paradoxically,
this mechanism could lead to AMPK activation and, consequently, mTORC1 inhibition. Results from
our own studies in female rats supplemented with simple sugars in liquid form for seven months
indicated that fructose does not activate hepatic AMPK [21], suggesting that if ATP depletion does
occur it may be transient and not associated with chronic fructose intake. In a recent study, Hu et al.
confirmed this transient inhibitory effect of fructose: in mice sacrificed 30 min after receiving a 10%
fructose or glucose solution by gavage, mTORC1 activity was inhibited by fructose but this inhibitory
effect was lost in mice receiving a diet containing 60% fructose for one week [22]. In contrast to
fructose, our results in female rats showed that chronic consumption of an equicaloric glucose solution
activated AMPK, as demonstrated by a modest but significant 30% increase in phospho-AMPK α
(Thr172) levels [21]. We attributed this effect to the increased plasma adiponectin levels observed
only in rats consuming glucose [9], as the liver has been described to be one of the main targets of
circulating adiponectin, which activates hepatic AMPK by phosphorylation [23].
Carbohydrates can also regulate mTORC1 activity through endoplasmic reticulum (ER) stress.
The ER has a key role in cellular homeostasis by controlling the synthesis, folding and posttranslational
modification of proteins. Perturbations in the ER folding capacity cause ER stress and trigger the
unfolded protein response (UPR), which involves the activation of specific transmembrane proteins
acting as stress sensors (activating transcription factor 6 [ATF6], inositol-requiring enzyme 1 [IRE1] and
protein kinase RNA-like ER kinase [PERK]) to restore cell homeostasis by proper protein folding and
reduction of the ER protein load [24]. The UPR is activated not only by the accumulation of unfolded
proteins but also by other stimuli, including nutrient availability. Both deprivation and excessive levels
of carbohydrates can induce ER stress, which may influence mTORC activity. Thus, glucose starvation
causes energy stress by reducing ATP levels, which at least in some cell types can induce calcium efflux
from the ER and activate the PERK branch of the UPR [25]. In addition, protein glycosylation occurs in
the ER and, therefore, alterations in this process due to glucose depletion could perturb ER homeostasis
and elicit also ER stress [18]. On the other hand, high levels of glucose stimulate ER stress in hepatic
cells, as shown by higher levels of PERK phosphorylation [26]. Interestingly, the glucose-induced ER
stress response in these cells is mediated by mTORC1, as specific mTORC1 inhibition by rapamycin
prevents the phosphorylation of PERK and its downstream effector eIF2α [26]. ER stress can also elicit
mTORC1 activation through ATF6 and the induction of the phosphoinositide 3-kinase (PI3K)-Akt axis;
however, Akt and mTORC1 are inhibited under conditions of chronic ER stress [27].
Results from our own studies in female rats showed that fructose consumption activated mTORC1
independently of ER stress [8,9]. As mentioned before, we observed that fructose induced hepatic
mTOR phosphorylation at Ser-2481 but the only UPR marker that was increased was phosphorylated
IRE1, whereas the PERK branch of the UPR remained unaffected [8,9]. In fact, mTOR activation in renal
cells has been shown to selectively induce IRE1 without affecting PERK and ATF6 [28]. In contrast
to PERK activation, which leads to CHOP induction and JNK-mediated apoptosis, selective IRE1
activation might protect cells by promoting the elimination of misfolded proteins without inducing cell
Int. J. Mol. Sci. 2019, 20, 1117 5 of 13
death. Moreover, as it was shown in hepatocyte-specific IRE1-null mice, IRE1 is required to prevent
hepatic steatosis [29] and when it is chronically activated it may cause the regression of pre-existing
steatosis. Accordingly, the lack of hepatic steatosis observed in rats supplemented with fructose or
glucose for seven months could be attributed to the selective and chronic activation of IRE1 in their
livers [9].
Interestingly, when we compared the effects of glucose and fructose supplementation in female
rats, we found that fructose induced hepatic mTOR Ser-2481 phosphorylation to a greater extent than
glucose and that only fructose activated downstream effectors of mTORC1 such as phosphorylated
4EBP1 [9]. The fact that fructose had a greater effect on mTORC1 than glucose could not be
attributed to the amount of energy provided by the sugar supplementation, as rats consumed
equicaloric amounts of glucose and fructose. Instead, this could be due to an indirect mechanism
involving changes in plasma insulin levels. Insulin, after binding to its receptor, activates the
PI3K-phosphoinositide-dependent kinase 1 (PDK1)-Akt pathway, leading to the phosphorylation of
TSC2 at multiple sites, which inactivates the TSC2/TSC1 complex and activates Rheb and mTORC1 [2].
Our results showed that only fructose-supplemented rats displayed significant hyperinsulinemia after
seven months of treatment and therefore, the lower level of mTORC1 activation observed with the
equicaloric glucose supplementation could be attributed, at least in part, to a lack of effect on plasma
insulin levels [9]. Another factor contributing to this differential effect is that, as commented before,
only glucose supplementation activates AMPK [9], which has an inhibitory effect on mTORC1.
3. The Effects of mTOR on Lipid Metabolism and Modulation by Carbohydrates
The mTOR system plays a key role in the response to nutrient abundance, in part by activating
anabolic processes such as lipid synthesis. Both mTORC1 and mTORC2 can modulate lipogenesis but
much more attention has been paid to mTORC1. Lipogenesis is activated by mTOR mainly through
the master regulator of this process, the transcription factor SREBP1c, which belongs to the basic-helix
loop-helix-leucine zipper family. SREBP1c is synthesized as a precursor that remains anchored
to the ER membrane through its interaction with SREBP cleavage-activating protein (SCAP) [30].
Through a mechanism that remains unclear [31], the SCAP-SREBP1c heterodimer is transferred to
the Golgi apparatus, where SREBP1c is processed by proteolytic enzymes into its mature form, that
then translocates to the nucleus to induce the transcription of target genes, including those encoding
the main lipogenic enzymes. The mTOR system can regulate SREBP1c activity at different levels,
including transcription of its encoding gene Srebf1, processing of the precursor protein and nuclear
transport of the mature protein (Figure 3) [2,31].
mTORC1 activates SREBP1c partly through S6K1 by mechanisms that have not been completely
elucidated [2]. For example, a study in rat hepatocytes in which the transcriptional effects of insulin on
the SREBP1c gene were eliminated showed that S6K1 is essential for SREBP1c processing but not for
its transcription [32]. However, other studies have shown that S6K1 depletion in the liver of obese
mice reduces the abundance of hepatic SREBP1c mRNA [33]. Moreover, a recent report showed that
mTORC1-S6K1 activation may induce lipogenesis independently of SREBP1c by promoting the splicing
of lipogenic mRNAs, that increases their stability [34]. In addition, mTORC1 may activate SREBP1c
via S6K1-independent pathways such as by: (i) the phosphorylation of CREB-regulated transcription
coactivator 2 (CRTC2), which increases the trafficking of SREBP1c to the Golgi apparatus where it is
processed [35]; (ii) the phosphorylation and nuclear exclusion of lipin-1, which prevents its blocking
effect on SREBP1c transcriptional activity [36]; and (iii) inducing ER stress, which may activate hepatic
SREBP1c [2]. Furthermore, mTORC2 might also regulate SREBP1c, as mice with specific hepatic
deletion of Rictor have been reported to show reduced SREBP1c activity and lipogenesis [37].
Thus, it could be hypothesized that simple sugars promote lipogenesis by activating the
mTORC1-SREBP pathway. Our studies in rats supplemented with 10% liquid fructose (w/v) for
two weeks or two months did not show increases in the nuclear active form of SREBP1c, despite
higher levels of mTOR phosphorylation [8,10]. By contrast, nuclear SREBP1c levels were significantly
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increased in rats fed a 63% fructose in solid form for two weeks [38]. Similarly, in our chronic study in
which 10% liquid sugars were supplemented for seven months, fructose but not glucose caused an
increase in nuclear SREBP1c [9]. Therefore, it seems that the ability of fructose to activate SREBP1c
depends on the burden of fructose to the organism, taking into account both the amount of fructose
consumed and the duration of the supplementation. Moreover, the different effects of fructose and
glucose on SREBP1c activity could be due to the greater effect of fructose on mTOR phosphorylation,
combined with the hyperinsulinemia caused by fructose but not glucose supplementation.
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been  reported  to  occur  in  different  cell  types  and  be  essential  for  regulating  cellular  energy 
metabolism, as it may be activated or inhibited in response to energy requirements [41]. Lipophagy 
is,  in  fact, a  specialized subtype of autophagy, using  the  same  intracellular machinery and being 
regulated by  the  same mechanisms as  those associated with autophagy,  including mTORC1  [39]. 
Repression of autophagy by mTORC1 involves  he phosphorylat on of ULK‐1 at Ser‐757 [42]. Our 
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supplementation for two months increased phosphorylated levels of ULK‐1 and led to a decrease of 
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Finally,  the mTOR  system may  also modulate  lipid  catabolism  by  inhibiting  fatty  acid  β‐
oxidation. This could be a consequence of the inhibition of autophagy by mTORC1, as autophagy 
causes the breakdown of triglycerides and provides fatty acid substrates for β‐oxidation. Activation 
Figure 3. Effects of mTORC1 on lipid metabolism. mTORC1 activates lipogenesis via SREBP1c,
partly through S6K1 and also by S6K1-independent mechanisms, such as the phosphorylation of
CRTC2 and lipin, which causes its nuclear exclusion, and ER stress induction. In addition, mTORC1
inhibits neutral lipolysis and repress autophagy/lipophagy by phosphorylating ULK-1, which could
inhibit fatty acid β-oxidation by lowering substrate availability. mTORC1 may also inhibit PPARα
activity by recruiting NCoR1 to the nucleus and by inducing lipin-1 phosphorylation.
mTOR affects lipid metabolism not only by inducing lipogenesis but also by inhibiting lipolysis
and lipophagy (Figure 3). Both mTORC1 and mTORC2 can inhibit neutral lipolysis, a process in which
cytoplasmic lipases hydrolyse cytoplasmic lipid droplets at a neutral pH [39]. The term lipophagy
was coined in 2009 when it was demonstrated that the intracellular lipid content is also regulated
by the lysosomal degradation of lipids through autophagy [40]. Since then, lipophagy has been
reported to occur in different cell types and be essential for regulating cellular energy metabolism,
as it may be activated or inhibited in response to energy requirements [41]. Lipophagy is, in fact,
a specialized subtype of autophagy, using the same intracellular machinery and being regulated by
the same mechanisms as those associated with autophagy, including mTORC1 [39]. Repression of
autophagy by mTORC1 involves the phosphorylation of ULK-1 at Ser-757 [42]. Our studies in female
rats revealed that increased phosphorylation of hepatic mTOR after fructose supplementation for
two months increased phosphorylated levels of ULK-1 and led to a decrease of autophagic markers,
including the LC3B-II/LC3B-I protein ratio [8]. As the inhibition of autophagy promotes hepatic
triglyceride accumulation, we hypothesized that this mechanism could be responsible, at least in part,
for the hepatic steatosis observed in rats sub-chronically supplemented with liquid fructose.
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Finally, the mTOR system may also modulate lipid catabolism by inhibiting fatty acid β-oxidation.
This could be a consequence of the inhibition of autophagy by mTORC1, as autophagy causes the
breakdown of triglycerides and provides fatty acid substrates for β-oxidation. Activation of mTORC1
and inhibition of autophagy could explain why β-oxidation is inhibited in the livers of female rats after
sugar supplementation for two and seven-month, without altering peroxisome proliferator-activated
receptor (PPAR)α gene or protein expression [8,9]. Despite a lack of effect on PPARα expression,
our results showed that the reduction of β-oxidation by fructose involved lower PPARα activity,
as indicated by the reduced nuclear PPARα levels in the livers of fructose-supplemented rats [9].
This could also be related to mTORC1 activation, as mTORC1 has been reported to inhibit PPARα at
least by two possible mechanisms, via nuclear receptor corepressor 1 (NCoR1) or lipin-1 [2]. NCoR1 is a
transcriptional regulator that binds to several nuclear receptors. The mTORC1 substrate S6K2 has been
observed to associate with NCoR1, recruiting it to the nucleus where it represses PPARα transcriptional
activity [43]. In hepatic cells lipin-1 acts as a transcriptional activator of β-oxidation genes through
PPARα activation. As it was previously mentioned, mTORC1 can induce the phosphorylation and
nuclear exclusion of lipin-1, which could lead to the reduction of PPARα activity. There are few studies
examining the effects of carbohydrates on lipin-1 in vivo. Vasiljević et al. reported that male rats
supplemented with 10% liquid fructose for nine weeks showed increased microsomal levels of lipin-1
in the liver, although the extent of lipin-1 phosphorylation or its concentration in hepatic nuclear
fractions were not determined [44]. Furthermore, despite the same treatment increased the nuclear
contents of lipin-1 in the hearts of female (but not male) rats, this was not accompanied by increased
levels of nuclear PPARα [45]. Moreover, it remains to be established whether this is a specific effect in
cardiac cells and whether it is related to mTOR activity.
4. The Effects of mTOR on Carbohydrate Metabolism
mTOR can affect carbohydrate metabolism directly, by controlling hepatic gluconeogenesis, and
also indirectly, by regulating pancreatic β-cell mass and activity (Figure 4). Moreover, both mTORC1
and mTORC2 can induce insulin resistance and, thus, dysregulate glucose metabolism.
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complex containing ChREBP and Max‐like protein (Mlx), inhibiting its translocation to the nucleus. 
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results in reduced TXNIP expression and protects β‐cells from apoptosis. Moreover, mTOR not only 
regulates  the  number  of  β‐cells  but  also  their  specific  activity,  as  mTOR  inactivation  by  the 
overexpression of a kinase‐dead mTOR mutant (which therefore affects both mTORC1 and mTORC2) 
leads to defective β‐cell function without affecting its mass [54]. 
Carbohydrates,  as well  as  other  nutrients,  can  regulate  β‐cell  proliferation  as  an  adaptive 
response to the changes in the metabolic environment. It has been recognized for a long time that 
glucose regulates not only insulin secretion but also the proliferation of β‐cells. However, the role of 
Figure 4. Effects of mTORC1 on carbohydrate metabolism. mTORC1 activation inhibits gluconeogenesis
by promoting the phosphorylation and nuclear exclusion of FoxO1 via S6K1, which blocks its
transcriptional effect on the main gluconeogenic genes PEPCK and G6Pase. Carbohydrate metabolism
may be also indirectly altered by mTORC1 effects on the survival and proliferation of insulin-secreting
pancreatic β-cells.
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The ability of mTORC1 to control gluconeogesis was demonstrated by experiments in
rapamycin-treated rats, which showed that chronic inhibition of the mTORC1-S6K1 pathway increased
the hepatic expression of the key gluconeogenic genes encoding phosphoenolpyruvate carboxykinase
(PEPCK) and glucose 6-phosphatase (G6Pase) in the liver [46]. The regulation of gluconeogenic
gene expression is mediated partly by the transcription factor forkhead box protein O1 (FoxO1).
In response to insulin, FoxO1 is phosphorylated by Akt causing its nuclear exclusion and a reduction
in PEPCK and G6Pase expression. Interestingly, it has been reported that in rapamycin-treated rats,
in which mTORC1 was inhibited, nuclear FoxO1 levels were increased despite hyperinsulinemia,
which could account for the increased expression of PEPCK and G6Pase [46]. Although that study
did not determine the extent of FoxO1 phosphorylation, Yue et al. [47] showed that the stimulation
of mTOR-S6K1 signalling in the mouse hypothalamus increased FoxO1 phosphorylation, whereas
treatment with rapamycin (which blocks only mTORC1 when it is administered acutely) reduced
FoxO1 phosphorylation. In addition, experiments in liver-specific Rictor knockout mice demonstrated
that mTORC2 also controls hepatic gluconeogenesis. Upon refeeding, these mice showed hepatic
FoxO1 hypophosphorylation and nuclear localization, together with higher levels of PEPCK and
G6Pase mRNA, compared to wild type mice [37]. mTORC2 phosphorylates Akt at Ser-473 and it
has been shown that in mTORC2-deficient cells phosphorylation at this position is absent and FoxO1
phosphorylation is specifically reduced [48].
Thus, it seems plausible that both mTORC1 and mTORC2 activation may inhibit gluconeogenesis
by promoting FoxO1 phosphorylation via S6K1 and Akt, respectively. Our results in female rats
supplemented with simple sugars support this hypothesis. In rats drinking a 10% w/v fructose
solution for two weeks, mTORC1 activation led to a decrease in PEPCK expression, probably
via IRE1 phosphorylation that promoted the splicing of X-box-binding protein (XBP)-1, which is
involved in the maintenance of glucose homeostasis [49]. Moreover, chronic glucose and fructose
supplementation in rats has been reported to activate mTORC1 (shown by the phosphorylation of
peroxisome proliferator-activated receptor gamma coactivator 1-alpha [PGC-1α], a direct target of
S6K1 and the absence of Ser-473 Akt phosphorylation), increase FoxO1 phosphorylation and reduce
the expression of PEPCK and G6Pase [9]. However, the crosstalk between mTORC1 and mTORC2
is quite complex, as cell culture experiments show that mTORC1-S6K1 signalling induce Rictor
phosphorylation, with Akt and FoxO1 phosphorylation increasing when the phosphorylation position
of Rictor is mutated [50]. This suggests that mTORC1 signalling could inhibit the mTORC2-Akt
pathway, leading to reduced FoxO1 phosphorylation and increased gluconeogenesis.
In addition, mTOR signalling regulates the growth and proliferation of pancreatic β-cells and
their ability to secrete insulin, which may also affect glucose homeostasis. Similar to the regulation
of gluconeogenesis, both mTOR complexes control β-cell mass and activity, as mice deficient in
S6K1 [51] or Rictor [52] exhibit reduced β-cell mass and hypoinsulinemia. The molecular mechanism
underlying these effects was recently unravelled [53]. In pancreatic β-cells, mTOR interacts with a
complex containing ChREBP and Max-like protein (Mlx), inhibiting its translocation to the nucleus.
The ChREBP-Mlx complex regulates the transcription of thioredoxin-interacting protein (TXNIP),
which is involved in the apoptosis of β-cells. Thus, the reduced nuclear translocation of ChREBP-Mlx
results in reduced TXNIP expression and protects β-cells from apoptosis. Moreover, mTOR not
only regulates the number of β-cells but also their specific activity, as mTOR inactivation by the
overexpression of a kinase-dead mTOR mutant (which therefore affects both mTORC1 and mTORC2)
leads to defective β-cell function without affecting its mass [54].
Carbohydrates, as well as other nutrients, can regulate β-cell proliferation as an adaptive response
to the changes in the metabolic environment. It has been recognized for a long time that glucose
regulates not only insulin secretion but also the proliferation of β-cells. However, the role of mTOR as
a key player in this process has been demonstrated only recently. The proliferative effect of glucose on
β-cells involves the activation of an atypical protein kinase C (PKCζ), which activates mTORC1 and
subsequently induces cyclin D2 activation [55,56]. Fructose might also have a proliferative effect of
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on pancreatic β-cells, given the ability of fructose to activate mTORC1. However, excessive fructose
consumption might be detrimental, as a high fructose diet (65% fructose in solid form) has been
reported to induce pancreatic ER stress and β-cell apoptosis, which are increased when fructose is
combined with a high fat diet [57].
5. Concluding Remarks
It is well recognized that overnutrition, together with a sedentary lifestyle, is one of the main
drivers of metabolic pathologies such as fatty liver, dyslipidaemia and hyperglycaemia. However, the
role of individual nutrients and the mechanisms involved have not been fully elucidated. From our
studies in rats supplemented with simple sugars in liquid form (10% w/v) for different periods of time
(from two weeks to seven months), we have identified hepatic mTOR, specifically mTORC1, as a key
hub that transduces the signals elicited by carbohydrates to activate or inhibit molecular pathways
and modulate the metabolism of lipids and carbohydrates. Thus, we have consistently observed that
glucose and fructose intake increases mTOR phosphorylation and activates mTORC1. Although the
specific underlying mechanism is not fully understood, we have ruled out the involvement of Rheb
availability or expression and we have also demonstrated that mTORC1 activation is independent
of ER stress. mTORC1 activation by glucose and fructose explains most of the metabolic effects
observed in our studies in female rats, including enhanced lipogenesis and reduced gluconeogenesis
(Figure 5). Moreover, mTORC1 activation might also inhibit PPARα activity and autophagy which,
together with enhanced lipogenesis, contribute to hepatic fat deposition. By these mechanisms
sub-chronic administration of fructose (for two months) induced hepatic steatosis in female rats.
However, sustained activation of the mTORC1-IRE1 pathway by chronic fructose supplementation
could prevent fat deposition in the liver. Moreover, the different extent of mTORC1 activation seems
to be responsible for the different effects of fructose and glucose supplementation in rats, as only
fructose-supplemented rats displayed significant hyperinsulinemia, which also activates mTORC1.
On the other hand, only glucose increases plasma adiponectin levels leading to AMPK activation,
which in turn inhibits mTORC1 and therefore has a weaker effect on mTORC1 activation than fructose.
The mechanism by which glucose increases adiponectin levels and whether this effect is specific to
rodents or may also apply to humans are yet to be established.
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Fructose activates mTORC1 leading to reduced gluconeogenesis and enhanced lipogenesis which,
together with PPARα/β-oxidation activity and autophagy inhibition contribute to hepatic fat deposition
observed in our studies after sub-chronic administration of fructose (for two months) in female rats.
By contrast, sustained activation of the mTORC1-IRE1 pathway by chronic fructose supplementation
could prevent fat deposition in the liver. Fructose-induced hyperinsulinemia, which activates mTORC1
and the increase in plasma adiponectin levels caused by glucose administration, which inhibits
mTORC1 via AMPK activation, lead to a different extent of mTORC1 activation by these simple sugars,
which seems to be responsible for the different metabolic effects of fructose and glucose supplementation
observed in our studies performed in female rats.
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prereceptor glucocorticoid metabolism and lipogenesis impair insulin signaling in the liver of fructose-fed
rats. J. Nutr. Biochem. 2013, 24, 1790–1797. [CrossRef] [PubMed]
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